[Early phase II trial of bestrabucil in hematological malignancies].
Thirty-three patients with various hematological malignancies were treated with Bestrabucil, the benzoate of an estradiol-chlorambucil conjugate, at doses of 50-300 mg daily p.o., consecutively. Nineteen patients had previously received chemotherapy. Of 29 evaluable patients, there were one CR and three PRs among 6 patients with chronic lymphocytic leukemia, two CRs and one PR among 4 patients with malignant lymphoma, two PRs among 3 patients with adult T-cell leukemia, one PR among 4 patients with macroglobulinemia, one PR for one patient with essential thrombocythemia, and one PR for a patient with chronic myelocytic leukemia. Main side effects included G1 symptoms (14%), estradiol-related symptoms (24%) and myelosuppression (32%).
Nagura
E
E
Ohno
R
R
Yamada
K
K
Akao
Y
Y
Naito
K
K
Nishikawa
M
M
Tanaka
H
H
Shirakawa
S
S
Ono
Y
Y
Ezaki
K
K
D000328:Adult; D000368:Aged; D002699:Chlorambucil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013921:Thrombocytopenia / Q000139:chemically induced
D002699:Chlorambucil; D004958:Estradiol; C036613:bestrabucil